Entero Healthcare Solutions Limited has informed the Exchange regarding Appointment of Mr Rajesh Shashikant Dalal as Non- Executive Independent Director of the company w.e.f. August 25, 2026.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions held its Board Meeting on May 25, 2026, approving audited financial results for Q4 and FY26. Standalone revenue from operations was Rs. 3,482.41 million (down from Rs. 4,086.70 million in FY25), while consolidated revenue grew significantly to Rs. 65,912.12 million from Rs. 50,957.80 million. Standalone profit after tax improved to Rs. 268.75 million (vs Rs. 191.81 million), and consolidated PAT rose to Rs. 1,458.40 million (vs Rs. 1,074.34 million). The Board also re-appointed three Non-Executive Independent Directors (Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma) for a second term of five years effective August 25, 2026, subject to shareholder approval. Additionally, 7,240 equity shares were allotted under the ESOP plan, and 7,300 fresh stock options were granted. The company also approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through its subsidiary.
Strong consolidated financial performance with 29% revenue growth demonstrates successful integration of acquisitions. The re-appointment of three independent directors for another five-year term indicates board stability and continuity of governance standards.